N/A N=212 Midlines and Thrombophlebitis
Catheter Infection · Catheter Thrombosis · Catheter Complications
Primary: Upper Extremity CR-UEVT — 7; 11 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=80 Comparison of Tesio and LifeCath Twin Permanent Dialysis Catheters
Hemodialysis
Primary: Blood Flow Rate at First Use After Insertion — 277; 383 mL/min
N/A N=165 Passive Disinfection Cap Compliance Study
Infection, Hospital
Primary: Disinfecting Barrier Cap Compliance — 98.43 percentage of connector with compliance
N/A N=217 Central Venous Access Study
Central Line Catheters
Primary: Adherence to Clinical Guidelines for Catheter Interventions and Management — 12; 0; 0; 11 # of catheter-related incidents
N/A N=152 Complications Associated With Central Venous Access in the NSICU: PICC vs CVC
PICC · Central Venous Catheter · Central Line
Primary: Participants With Complications With Central Access Including Insertion — 14; 10 Participants — p=0.271
N/A N=101 Observational Study of Complications Related to Use of Peripherally Inserted Central Catheters
Adult Patients With Peripherally Inserted Central Catheters
Primary: Rate of PICC Line Occlusions — 37 percentage of enrolled subjects
Phase 4 N=13 Antifungal Locks to Treat Fungal-related Central Line Infections
Central Line Fungal Infections
Primary: Number of Patients With 2 Negative Fungal Cultures After 5 Days of Combined Systemic Antifungal and Antifungal Lock Therapy and the CVC Was Not Removed — 10; 3…
N/A N=35 Comparing Peripherally Inserted Central Catheters to Long Peripheral Catheters in Pediatrics
Vascular Access Device Complications
Primary: Percent Eligible Patients That Agreed to Participate — 80 percentage of eligible patients agreed t
Phase 3 N=95 Ethanol Lock Therapy for Treatment and Secondary Prophylaxis of Central Line-Associated Bloodstream Infection
Central Line-Associated Bloodstream Infection
Primary: Percentage of Therapeutic Failures (Early or Late Failure) in Children and Adolescents With CLABSI Receiving Standard Care Plus Ethanol Lock Therapy (ELT) vs. Standard…
N/A N=599 Dialysis Catheter Comparative Clinical Trial
End Stage Renal Disease
Primary: First Catheter Induced Complication — 78; 77 percentage of participants
Phase 2 N=20 t-PA Prophylaxis to Prevent Catheter-associated Thrombosis and Infection
Central Venous Catheter Thrombosis · Central Venous Catheter Associated Bloodstream Infection
Primary: Catheter-associated Venous Thrombosis — 3; 3 Participants
N/A N=149 Hub Cleansing to Prevent Hub Infection
Bacteremia
Primary: Number of Central Venous Catheter Hubs With Internal Contamination — 42; 18; 39; 14 contaminated hubs
N/A N=16 Community Central Line Infection Prevention Trial
Infection
Primary: Total Number of Central Line Associated Blood Stream Infections (CLABSI) — 113; 84; 123; 109 infections
N/A N=270 Ultrasound Guided Catheter Length Survivability
Catheter Complications
Primary: Duration of IV Survival — 92; 136 hours
N/A N=88 Blood Sampling Functionality of Extended Dwell Catheters
IV Catheter-Related Infection or Complication · Vascular Access Complication · Peripheral Venous Access
Primary: Blood Sampling Functionality — 70.19; 112.9 hours
Phase 2 N=60 Safety and Effectiveness of Novel Nitroglycerin Based Catheter Lock Solution
Catheter-Associated Infections · Catheter-Related Infections
Primary: Number of Participants With Drug-Related Hypotension — 0 Participants
N/A N=339 Peripherally Inserted Central Catheter (PICC) Thrombosis: Reverse Taper Versus Non-tapered Catheters
Venous Thrombosis
Primary: Evidence of PICC-related Venous Thrombosis — 102; 95 Participants
N/A N=50 Ultrasound-Guided Peripheral Venous Access Using AccuCath
Intravenous Access
Primary: First Attempt Success Rate — 17; 11 Participants
N/A N=248 AccuCath Guidewire Intravenous (IV) Device Versus Conventional IV Catheter In General Nursing Use
Vascular Access Complication
Primary: First Attempt Success Rate With Peripheral IV Catheter Placement — 89; 47 percentage of participants — p=<0.0001
N/A N=25 Catheter Placement for Hepatic Hydrothorax
Pleural Effusion
Primary: Feasibility of Using Indwelling Tunneled Pleural Catheters for the Management of Hepatic Hydrothorax — 25 Participants
Phase 3 N=806 Study Assessing Safety & Effectiveness of a Catheter Lock Solution in Dialysis Patients to Prevent Bloodstream Infection
Kidney Failure, Chronic · Catheter-Related Infections
Primary: Presence of a CAC-Adjudicated Catheter-Related Bloodstream Infection (CRBSI) in Subjects Receiving Hemodialysis for the Treatment of End Stage Renal Disease (ESRD)…
N/A N=120 Prospective Feasibility Trial of AccuCath 2.25" Blood Control (BC) Placed in Difficult Access Patients in the Emergency Department
Vascular Access Complication
Primary: First Attempt Success Rate — 92 Participants
Phase 4 N=303 Prophylactic Antimicrobial Catheter Lock
Bacteremia
Primary: Rate of Device-related Bacteremia — 30; 11 Number of infections
N/A N=220 Comparison of AccuCath IV Catheter and Conventional IV Catheter in Interventional Radiology
Vascular Access Complications
Primary: First Attempt Success Rate With Peripheral IV (PIV) Catheter Placement — 84; 90 Participants
N/A N=20 Compass Device CVC Trial
Blood Pressure
Primary: Operator Satisfaction — 8 score on a scale
N/A N=95 AccuCath™ Intravenous (IV) Device Used by Vascular Access Team (VAT)
Vascular Access Complication
Primary: Percentage of Participants With Successfully Inserted Peripheral IV Catheter Placement on First Attempt — 85.3 percentage of participants
N/A N=212 Ultrasound Guided Vascular Access in Pediatric Intensive Care Patients
Critical Illness
Primary: Central Line Placement Success — 82; 108 participants — p=<0.001
N/A N=1,229 Product Evaluation for the Effectiveness of the ClearGuard™ HD End Cap
End Stage Renal Disease (ESRD)
Primary: Positive Blood Cultures (PBCs) Per 1,000 Central Venous Catheter (CVC)-Days — 0.26; 0.59 PBCs per 1,000 CVC-days
N/A N=80 Impact of PIVC Length and Gauge on Catheter Indwell Time
Indication for Peripheral Intravenous Catheterisation
Primary: Patent Indwell Time Between PIVCs of Different Length and Gauge. — 40.19; 42.96; 35.91; 36.91 hours
Phase 3 N=177 Chlorhexidine Gluconate Cleansing in Preventing Central Line Associated Bloodstream Infection and Acquisition of Multi-drug Resistant Organisms in Younger Patients With Cancer or Undergoing Donor Stem Cell Transplant
Bacterial Infection · Benign Neoplasm · Malignant Neoplasm
Primary: Central Line-associated Bloodstream Infections (CLABSI) Events During the At-risk Days — 5.44; 3.1 CLABSI per 1000 at-risk days.